OncoMatch/Clinical Trials/NCT05877872
Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
Is NCT05877872 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Adjuvant immunotherapy for nasopharyngeal carcinoma.
Treatment: Adjuvant immunotherapy — The goal of this clinical trial is to compare efficacy of two different resection extension in patients with resectable recurrent nasopharyngeal carcinoma after induction chemotherapy. The main question it aims to answer is that whether tumor regress areas after induction chemotherapy required complete resection. Patients will be randomly assigned to receive reduced-target resection or full-target resection after induction chemotherapy. Researchers will compare these two groups to see if the efficacy of reduced-target resection is not inferior to full-target resection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RECURRENT T1, RECURRENT T2, RECURRENT T3 (AJCC 8th edition)
Excluded: Stage RECURRENT N1-3
recurrent T1 (the tumor is confined in nasopharynx, oropharynx and/or nasal cavity without parapharyngeal involvement); recurrent T2 (the tumor is confined in the superficial parapharyngeal spacer and is more than 0.5cm far from the internal carotid artery) and recurrent T3 (the tumor is confined in the base wall of the sphenoid sinus and is more than 0.5cm far from the internal carotid artery and cavernous sinus) (according to the 8th edition of American Joint Committee on Cancer (AJCC) staging system for nasopharyngeal carcinoma). Unresectable recurrent regional lymph node diseases (recurrent N1-3) with prevertebral fascia, cervical vertebrae, or common/internal carotid artery involvement (according to the 8th edition of AJCC staging system).
Performance status
KARNOFSKY 71–100
Karnofsky Performance Status (KPS) ≤70 [excluded]
Prior therapy
Must have received: platinum-based chemotherapy (gemcitabine, paclitaxel, platinum) — induction
After 3 cycles induction chemotherapy (Platinum based chemotherapy [gemcitabine/paclitaxel and platinum] and immunotherapy [PD-1/PD-L1 antibody] or a GAP regmen [gemcitabine, Apatinib and immunotherapy [PD-1/PD-L1 antibody]])
Must have received: immunotherapy (PD-1 antibody, PD-L1 antibody) — induction
After 3 cycles induction chemotherapy (Platinum based chemotherapy [gemcitabine/paclitaxel and platinum] and immunotherapy [PD-1/PD-L1 antibody] or a GAP regmen [gemcitabine, Apatinib and immunotherapy [PD-1/PD-L1 antibody]])
Must have received: GAP regimen (gemcitabine, apatinib, PD-1 antibody, PD-L1 antibody) — induction
GAP regmen [gemcitabine, Apatinib and immunotherapy [PD-1/PD-L1 antibody]]
Cannot have received: PD-1 inhibitor
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) agent.
Cannot have received: PD-L1 inhibitor
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) agent.
Cannot have received: CTLA-4 inhibitor
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) agent.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify